<html lang="en">

<head>
  <title>Pediatric Asthma</title>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width,initial-scale=1.0" />
  <link rel="stylesheet" href="cpgPedEr.css" />

</head>

<body>
  <div id="header-container"></div>
  <header class="page-header">Pediatric Asthma</header>

  <div class="container">
    <p class="cpg-headers">DEFINITION</p>
    <p class="cpg-text">
      Chronic inflammatory condition of the lung airways resulting in episodic
      airflow obstruction
    </p>
    <div class="border-btm"></div>
    <p class="cpg-headers">DIAGNOSIS</p>
    <ul>
      <li>
        <b>No standard</b> test to diagnose asthma, pulmonary function test
        can help a lot, if the child can perform it (usually above 6 years)
      </li>
      <li>
        The presence of <b>intermittent dry cough</b> and
        <b>expiratory wheezes</b> that respond to bronchodilators with the
        exclusion of other risk factors in a child, is the mainstay of asthma
        diagnosis
      </li>
      <li>
        For children aged <b>5 years</b> or less, where lung function tests
        cannot be effectively carried out, differential diagnoses should be
        given careful consideration, including but not limited to, assessment
        of the following:
      </li>
    </ul>
    <ol class="cpg-text">
      <li>Allergic rhinitis and allergic sinusitis</li>
      <li>Obstructions involving large airways</li>
      <li>Obstructions involving small airways</li>
      <li>Viral bronchiolitis or obliterative bronchiolitis</li>
      <li>Cystic fibrosis</li>
      <li>Bronchopulmonary dysplasia</li>
      <li>Heart disease</li>
      <li>Medication induced</li>
    </ol>

    <div class="border-btm"></div>

    <p class="cpg-text">
      <span><b>Any of the following symptoms must be considered for diagnosis of
          asthma in children:</b>
      </span>
    </p>
    <ol class="cpg-text">
      <li>Recurrent breathlessness, chest tightness, wheezing or cough.</li>
      <li>Often worse at night and early morning.</li>
      <li>Signs of airway obstruction.</li>
      <li>
        Symptoms follow viral RTI, exercise, emotions or exposure to
        aeroallergens or irritants.
      </li>
      <li>Improve with bronchodilators and anti-inflammatory therapy.</li>
      <li>Absence of seasonal variation in wheeze.</li>
      <li>Personal history of atopy.</li>
      <li>Wheeze heard on auscultation.</li>
      <li>
        Improvements of symptoms or lung function in response to adequate
        therapy.
      </li>
      <li>
        Presence of one major risk factor (parental history of asthma or
        eczema) or two of three minor risk factors (eosinophilia, wheezing
        without colds, and allergic rhinitis).
      </li>
    </ol>

    <div class="border-btm"></div>
    <p class="cpg-headers">ASTHMA EXACERBATION MANAGEMENT</p>
    <p class="cpg-text">
      <span>Assessment of asthma severity should be performed to all patients
        presented to the ER with asthma exacerbation
      </span>
    </p>

    <table class="cpg-table">
      <tr style="background: #c9c9c9">
        <th></th>
        <th>Mild</th>
        <th>Moderate</th>
        <th>Severe</th>
        <th>Life-threatening</th>
      </tr>
      <tr>
        <td><b>Mental state</b></td>
        <td>Normal</td>
        <td>Normal</td>
        <td>Agitated</td>
        <td>Confused/Drowsy</td>
      </tr>
      <tr>
        <td><strong>Accessory muscles</strong></td>
        <td>Not used</td>
        <td>Some use</td>
        <td>Moderate-marked use</td>
        <td>Maximal use, Exhaustion &plusmn;, central cyanosis</td>
      </tr>
      <tr>
        <td>
          <strong>Initial SpO<sub>2</sub></strong>
        </td>
        <td>95%</td>
        <td>90-95%</td>
        <td>&lt;90%</td>
        <td>&lt; 85%</td>
      </tr>
      <tr>
        <td><strong>Pulse</strong></td>
        <td>Normal</td>
        <td>Tachycardia</td>
        <td>Tachycardia</td>
        <td>Marked tachycardia</td>
      </tr>
      <tr>
        <td><strong>Talk</strong></td>
        <td>sentences</td>
        <td>phrases</td>
        <td>single words</td>
        <td>Unable to talk</td>
      </tr>
      <tr>
        <td><strong>Lung Sounds</strong></td>
        <td>Wheeze + normal breath sounds</td>
        <td>Wheeze &plusmn; reduced breath sounds</td>
        <td>Wheeze &plusmn; reduced breath sounds</td>
        <td>Quiet chest</td>
      </tr>
      <tr>
        <td colspan="5">
          <em>Adapted with modifications from Global initiative of asthma 2022
            update
          </em>
        </td>
      </tr>
      <tr>
        <td colspan="5">
          <strong>Notes</strong>
          <br />
          If a patient has signs and symptoms that cross categories always
          treat according to their most severe features.
          <br />
          If the child has received treatment prior to arrival, manage as more
          severe than the clinical signs indicate.
        </td>
      </tr>
    </table>

    <br />
    <br />
    <p class="cpg-sub-headers">Breathing rates in awake children</p>
    <table class="cpg-table">
      <tr style="background: #c9c9c9">
        <th><strong>Age </strong></th>
        <th><strong>Normal&nbsp; rate</strong></th>
      </tr>
      <tr>
        <td>&lt;2 months</td>
        <td>&nbsp;&lt;60/minute</td>
      </tr>
      <tr>
        <td>2&ndash;12 months</td>
        <td>&lt;50/minute</td>
      </tr>
      <tr>
        <td>1&ndash;5 years</td>
        <td>&lt;40/minute</td>
      </tr>
      <tr>
        <td>6&ndash;12 years</td>
        <td>&lt;30/minute</td>
      </tr>
      <td colspan="2">
        <em>Adapted from Global initiative of asthma 2023 update </em>
      </td>
    </table>
    <br />
    <div class="border-btm"></div>
    <p class="cpg-sub-headers">Heart rates in children</p>
    <table class="cpg-table">
      <tr style="background: #c9c9c9">
        <th><strong>Age </strong></th>
        <th><strong>Normal&nbsp; rate</strong></th>
      </tr>
      <tr>
        <td>2&ndash;12 months</td>
        <td>&lt;160/minute</td>
      </tr>
      <tr>
        <td>1&ndash;2 years</td>
        <td>&lt;120/minute</td>
      </tr>
      <tr>
        <td>2&ndash;12 years</td>
        <td>&lt;110/minute</td>
      </tr>
      <td colspan="2">
        <em>Adapted from Global initiative of asthma 2022 update</em>
      </td>
    </table>

    <br />
    <div class="border-btm"></div>
    <p class="cpg-sub-headers">Asthma exacerbation management Action plan</p>

    <table class="cpg-table">
      <tr style="background: #c9c9c9">
        <td><strong>Level of severity</strong></td>
        <td><strong>Action</strong></td>
      </tr>
      <tr>
        <td>Mild</td>
        <td>
          Manage at ER and discharge, unless the case shifted to more severe
          level.
        </td>
      </tr>
      <tr>
        <td>Moderate</td>
        <td>
          Manage at ER and reassess the need for admission by Pediatrician.
        </td>
      </tr>
      <tr>
        <td>Severe</td>
        <td>Admit to Pediatric ward</td>
      </tr>
      <tr>
        <td>Life- threatening</td>
        <td>Admit to ICU</td>
      </tr>
      <tr>
        <td colspan="2">
          <ul>
            <li>
              Moderate and above should be managed by
              <strong>Pediatric</strong> staff.
            </li>
            <li>
              A patient may move between levels of asthma severity whilst
              receiving treatment.&nbsp; It is important to be continually
              aware of indications that severity level has changed.
            </li>
            <li>Continually refer to assessed of asthma severity</li>
          </ul>
          <p>
            The patient should have most of the lower severity level features
            to be shifted from one severity to the milder one.
          </p>
        </td>
      </tr>
    </table>

    <p class="cpg-headers">MILD SEVERITY MANAGEMENT</p>
    <ul class="cpg-text">
      <li>
        Inhaled SABA by nebulizer (or MDI with valved holding chamber) &plusmn;
        ipratropium bromide &plusmn; Oxygen, up to 3 doses in first hour.
      </li>
      <ul>
        <li><b>SABA is superior to ipratropium (see notes)</b></li>
      </ul>
      <li>
        Oral systemic corticosteroids if no immediate response or if the patient
        recently took oral systemic corticosteroids.
      </li>
      <li>Reassess after each nebulizer.</li>
      <li>Continue treatment 1-3 hours, provided there is improvement.</li>
      <li>Make admission decision in less than 4 hours</li>
      <li>If there is good response:</li>
      <ul>
        <li>Discharge home.</li>
        <li>Continue treatment with inhaled SABA.</li>
        <li>Continue course of oral systemic corticosteroid.</li>
        <li>Consider initiation of an ICS.</li>
      </ul>
      <li>Patient education:</li>
      <ul>
        <li>Review medications, including inhaler technique.</li>
        <li>Review predisposing factors.</li>
        <li>Recommend follow up with pediatrician within 1 week.</li>
      </ul>
    </ul>
    <div class="border-btm"></div>
    <p class="cpg-headers">MODERATE SEVERITY MANAGEMENT</p>
    <ul class="cpg-text">
      <li>Start with the following medications:</li>
      <ul>
        <li>Salbutamol (neb) every 2hr &plusmn; Oxygen.</li>
        <li>Steroids (IV or PO).</li>
        <li>Hydration.</li>
      </ul>
      <li>Assess after 4 hours.</li>
      <ul>
        <li>If the child is not improving follow the severe management.</li>
        <li>If the child is improving:</li>
        <ul>
          <li>
            Decrease frequency of nebulizers gradually by increasing 1 hour
            each time to &#8805;4 hourly.
          </li>
          <li>Assess each 6 hour.</li>
          <ul>
            <li>If the child is not improving:</li>
            <ul>
              <li>Continue on present treatment.</li>
              <li>Add Ipratropium (nebulizer).</li>
              <li>Search for predisposing cause.</li>
              <li>Consider other diagnosis.</li>
            </ul>
            <li>If the child is improving:</li>
            <ul>
              <li>
                Apply discharge criteria, if fulfilled, discharge patient.
              </li>
            </ul>
          </ul>
        </ul>
      </ul>
    </ul>

    <div class="border-btm"></div>

    <p class="cpg-headers">SEVERE SEVERITY MANAGEMENT</p>
    <ul class="cpg-text">
      <li>Start with the following medications:</li>
      <ul>
        <li>Oxygen.</li>
        <li>Salbutamol (nebulizer) hourly.</li>
        <li>Steroids (IV/PO).</li>
        <li>Ipratropium (nebulizer).</li>
        <li>Hydration.</li>
      </ul>
      <li>
        Monitor SpO<sub>2</sub>.
      </li>
      <li>Chest X-ray.</li>
      <li>Assess after 3 hrs.</li>
      <ul>
        <li>If the child is not improving</li>
        <ul>
          <li>consider advanced management like magnesium sulphate</li>
          <li>
            consider communicating with pediatric pulmonologist and
            transferring the patient
          </li>
        </ul>
        <li>If the child is improving:</li>
        <ul>
          <li>
            Decrease frequency of nebulizers gradually by increasing 1 hour
            each time to &#8805;2hourly.
          </li>
          <li>Assess each 3 hours.</li>
          <li>
            If the child continues to improve manage as moderate severity.
          </li>
        </ul>
      </ul>
    </ul>

    <div class="border-btm"></div>
    <p class="cpg-headers">DISCHARGE CRITERIA</p>
    <ul>
      <li>Severity assessment not above mild level</li>
      <li>
        Patient on no more frequently than 4th hourly inhaled bronchodilator
        and off supplemental oxygen
      </li>
      <li>Pulse Oximetry 95% or above</li>
      <li>Normal feeding for age no dehydration or IV fluid needs</li>
      <li>
        Appropriate timing of discharge i.e., social factors favorable,
        parents/family able to care for child at home.
      </li>
    </ul>

    <div class="border-btm"></div>
    <p class="cpg-headers">DISCHARGE PLAN</p>
    <ul>
      <li>Parent &amp; Patient education</li>
      <li>Environmental control measures (predisposing factors)</li>
      <li>Review medications, their benefits and side effects</li>
      <li>Inhaler technique demonstration</li>
      <li>Home exacerbation management</li>
      <li>Supply medications and devices</li>
      <li>Organize and explain follow up with Pediatrician</li>
      <li>Asthma discharge summary is complete</li>
      <li>Asthma Management Plan provided to the family</li>
    </ul>

    <div class="border-btm"></div>
    <p class="cpg-sub-headers">Dosages of drugs for asthma exacerbations:</p>

    <table class="cpg-table" id="asthmaDrugs">
      <tr style="background: #c9c9c9">
        <th>Medication</th>
        <th>Dose</th>
        <th>Comment</th>
      </tr>
      <tr>
        <td>
          <b>Salbutamol</b> <br />
          Nebulizer solution
        </td>
        <td>
          0.15 mg/kg (<b>minimum dose 2.5 mg</b>) every 20 minutes for 3 doses
          then 0.15&ndash;0.3 mg/kg up to 10 mg every 1&ndash;4 hours as
          needed, or 0.5 mg/kg/hour by continuous nebulization
        </td>
        <td>
          Only selective beta 2&ndash;agonists are recommended. For optimal
          delivery, dilute aerosols to <b>minimum of 3 ml</b> at gas flow of
          6&ndash;8 L/min. Use large volume nebulizers for continuous
          administration. May mix with Ipratropium nebulizer solution.
        </td>
      </tr>
      <tr>
        <td>
          <b>Salbutamol</b><br />
          MDI (90 mcg/puff)
        </td>
        <td>
          4&ndash;10 puffs every 20 minutes for 3 doses, then every 1&ndash;4
          hours inhalation maneuver as needed. Use VHC; add mask in children
          &lt;4 years.
        </td>
        <td>
          In mild&ndash;to&ndash;moderate exacerbations MDI plus VHC is as
          effective as nebulized therapy with appropriate administration
          technique and coaching by trained personnel.
        </td>
      </tr>
      <tr>
        <td>
          <b>Ipratropium bromide</b><br />
          Nebulizer solution (0.25 mg/ml)
        </td>
        <td>0.25&ndash;5 mg every 20 minutes for 3 doses, then as needed</td>
        <td>
          May be used for up to 3 hours in the initial management of severe
          exacerbations.<br />
          <b>The Addition of Ipratropium to Albuterol has not been shown to
            provide further benefit
          </b>
          the patient is hospitalized.
        </td>
      </tr>
      <tr>
        <td>
          <b>Systemic Corticosteroids:</b><br />
          Prednisone, Methylprednisolone, Prednisolone
        </td>
        <td>1-2 mg/kg in 2 divided doses (maximum = 60 mg/day)</td>
        <td>
          For outpatient burst, use 12 mg/kg/day maximum 60 mg/day for
          3&ndash;10 days.
        </td>
      </tr>
      <tr>
        <td><b>Hydration</b></td>
        <td>100 ml/kg/24 hr D5 NS</td>
        <td>
          Calculate dehydration if present, Pay attention to patient medical
          diseases
        </td>
      </tr>
      <tr>
        <td style="background: #c9c9c9" colspan="3">Second line therapies</td>
      </tr>
      <tr>
        <td><b>Magnesium Sulfate (IV)</b></td>
        <td>
          0.1&ndash;0.2 mmol/kg (Maximum 10 mmol) or 25-75 mg/kg Max (2.5 gm)
          slow infusion 20-60 min
        </td>
        <td>
          Avoid magnesium sulfate in children younger than 2 years
          <br />Dilute in isotonic solution (normal saline) Monitor blood
          pressure
        </td>
      </tr>
      <tr>
        <td colspan="3">
          <b>Notes:</b> <br />
          <ul>
            <li>
              There is no known advantage for higher doses of corticosteroids
              in severe asthma exacerbations, nor is there any advantage for
              intravenous administration over oral therapy provided
              gastrointestinal transit time or absorption is not impaired.
            </li>
            <li>
              The total course of systemic corticosteroids for an asthma
              exacerbation requiring an Emergency Room visit of
              hospitalization may last from 3 to 10 days.
            </li>
            <li>
              For corticosteroid courses of less than 1(one) week, there is no
              need to taper the dose. For slightly longer courses (e.g., up to
              10 days), there probably is no need to taper, especially if
              patients are concurrently taking ICSs.
            </li>
            <li>
              ICSs can be started at any point in the treatment of an asthma
              exacerbation.
            </li>
          </ul>
        </td>
      </tr>
      <tr>
        <td colspan="3">
          <em>Adapted from Global initiative of asthma 2023 update</em>
        </td>
      </tr>
    </table>
    <br />
    <div class="border-btm"></div>
    <p class="cpg-headers">OPD ASTHMA FOLLOW-UP</p>

    <p class="cpg-sub-headers">Levels of Asthma control in children</p>
    <br />
    <table class="cpg-table">
      <tr style="background: #c9c9c9">
        <th>Characteristics</th>
        <th>Controlled <br />(All of the following)</th>
        <th>
          Partly controlled <br />
          (Any measure presents in any week)
        </th>
        <th>
          Uncontrolled <br />
          (â‰¥3 of any features of the partly controlled asthma in any week)
        </th>
      </tr>
      <tr>
        <td>Daytime symptoms</td>
        <td>None (&lt;2/week)</td>
        <td>&gt;2 days/week</td>
        <td>&gt;2 days/week</td>
      </tr>
      <tr>
        <td>Limitations of activities</td>
        <td>None</td>
        <td>Any</td>
        <td>Any</td>
      </tr>
      <tr>
        <td>Need for bronchodilator</td>
        <td>&#8804;2 days/week</td>
        <td>&gt;2 days/ week</td>
        <td>&gt;2 days/ week</td>
      </tr>
    </table>
    <br />
    <div class="border-btm"></div>
    <p class="cpg-headers">OUTPATIENT MANAGEMENT OF ASTHMA FOR CHILDREN</p>


    <ul>
      <li><b>STEP 1 :(all ages)</b></li>
      <ul>
        <li> Short-acting beta-agonist (PRN)</li>
        <li>If used more than 2 days per week (other than for exercise) consider inadequate control and the need to step
          up treatment.</li>
      </ul>
      <li><b>STEP 2</b></li>
      <ul>
        <li>All Ages</li>
        <ul>
          <li>Preferred: Low-dose inhaled steroid</li>
          <li>Alternative: Leukotriene blocker or cromolyn</li>
        </ul>
        <li>Age 0-4 Yrs </li>
        <ul>
          <li>Consider referral (especially if diagnosis is in doubt)</li>
        </ul>
      </ul>
      <li><b>STEP 3</b></li>
      <ul>
        <li>Age 12+ Yrs </li>
        <ul>
          <li>Preferred: Low-dose inhaled steroid + long-acting beta agonist or Medium-dose inhaled steroid</li>
          <li>Alternative: Low-dose inhaled steroid + leukotriene blocker</li>
        </ul>
        <li>Age 5-11 Yrs</li>
        <ul>
          <li>Low-dose inhaled steroid + long-acting beta agonist or leukotriene blocker or Medium-dose inhaled steroid
          </li>
        </ul>
        <li>Age 0-4 Yrs</li>
        <ul>
          <li>Medium-dose inhaled steroid + referral</li>
        </ul>
      </ul>
      <li><b>STEP 4</b></li>
      <ul>
        <li>Age 12+ Yrs</li>
        <ul>
          <li>Preferred: Medium-dose inhaled steroid + long-acting beta agonist</li>
          <li>Alternative: Medium-dose inhaled steroid + leukotriene blocker</li>
        </ul>
        <li>Age 5-11 Yrs</li>
        <ul>
          <li>Same as 12+ yrs</li>
        </ul>
        <li>Age 0-4 Yrs</li>
        <ul>
          <li>Medium-dose inhaled steroid + either long-acting beta-agonist or leukotriene blocker</li>
        </ul>
      </ul>
      <li><b>STEP 5</b></li>
      <ul>
        <li>Age 12+ Yrs</li>
        <ul>
          <li>High-dose inhaled steroid + long-acting beta agonist and Consider omaluzimab if allergies</li>
        </ul>

        <li>Age 5-11 Yrs</li>
        <ul>
          <li>Preferred: High-dose inhaled steroid + long-acting beta agonist</li>
          <li>Alternative: High-dose inhaled steroid + leukotriene blocker</li>
        </ul>

        <li>Age 0-4 Yrs</li>
        <ul>
          <li>High-dose inhaled steroid + either long-acting beta-agonist or leukotriene blocker</li>
        </ul>

      </ul>
      <li><b>STEP 6</b></li>
      <ul>
        <li>Age 12+ Yrs</li>
        <ul>
          <li>High-dose inhaled steroid + long-acting beta agonist + oral steroid and Consider omaluzimab if allergies
          </li>
        </ul>

        <li>Age 5-11 Yrs</li>
        <ul>
          <li>Preferred: High-dose inhaled steroid + long-acting beta agonist </li>
          <li>Alternative: High-dose inhaled steroid + leukotriene blocker + oral steroid</li>
        </ul>

        <li>Age 0-4 Yrs</li>
        <ul>
          <li>High-dose inhaled steroid + either long-acting beta-agonist or leukotriene blocker + oral steroid</li>
        </ul>

      </ul>

      <ul>

      </ul>

    </ul>


    <p class="cpg-headers">NOTES</p>
    <ul>
      <li><b>Step up:</b> step up if there is no improvement and Re-assess in 2 to 6 weeks, always address possible poor
        adherence to medication.</li>
      <li><b>Step down:</b> if well controlled and re-assess in 3 months. If very stable then assess control every 3 to
        6 months.</li>
      <li><b>Intermittent Asthma</b> is managed by step 1</li>
      <li><b>Persistent Asthma</b> needs Daily Medications and managed by steps 2 to 6 </li>
      <li>All <b>LABAs</b> and combination agents containing LABAs have a black box warning.</li>

      <li>
        Patients on salbutamol inhaler only, should have no limitations of
        activities, no Nocturnal or daytime symptoms
      </li>
      <li>
        <b>ICS</b> (inhaled steroids) are <b>superior</b> to LTRA: Leukotriene Receptor
        Antagonist used as second step therapy
      </li>
      <li>
        LTRA can be beneficial in patients with comorbid <b>allergic rhinitis</b> and young children with recurrent
        viral-induced exacerbations</li>
      <li>
        long-acting beta agonists (LABAs) is adjuvant therapy and should not
        be used alone in pediatrics
      </li>
      <li>the use of LABAs below 5 years of age not fully studied</li>

      <li>
        If clear benefit is not observed within <b>4-6 weeks</b> and
        patient/family medication technique and adherence are satisfactory,
        consider <b>adjusting therapy</b> or <b>alternative diagnosis</b>.
      </li>
      <li>
        Before diagnosis of <b>Cough variant asthma</b> rule out post nasal
        drip (chronic upper airway cough syndrome), allergic rhinitis,
        gastroesophageal reflux (GERD) and vocal cord dysfunction
      </li>
    </ul>

    <div class="border-btm"></div>
    <p class="cpg-headers">FOLLOW-UP OF PATIENT ON INHALED STEROIDS</p>
    <ul>
      <li><b>Low- to medium-dose ICS</b></li>
      <ul>
        <li>Monitor blood pressure and weight with each physician visit</li>
        <li>
          Measure height annually; monitor periodically for declining growth
          rate and pubertal developmental delay
        </li>
        <li>Encourage regular physical exercise</li>
        <li>
          Ensure adequate dietary calcium and vitamin D with additional
          supplements for daily calcium if needed
        </li>
        <li>Avoid smoking</li>
        <li>
          Ensure TSH status if patient has history of thyroid abnormality
        </li>
      </ul>
      <li><b>High-dose ICS, at least 4 courses oral corticosteroid/yr</b></li>
      <ul>
        <li>
          Yearly ophthalmologic evaluations to monitor for cataracts or
          glaucoma
        </li>
        <li>Baseline bone densitometry (DEXA scan)</li>
        <li>
          Consider patient at increased risk for adrenal insufficiency,
          especially with physiologic stressors (e.g., surgery, accident,
          significant illness)
        </li>
        <li>Choosing an Inhaler Device for Children with Asthma</li>
      </ul>
    </ul>

    <div class="border-btm"></div>
    <br />
    <p class="cpg-headers">LIST OF EQUIPOTENT</p>

    <table class="cpg-table" id="">
      <tr style="background: #c9c9c9">
        <th>Age group</th>
        <th>Preferred Device</th>
        <th>Alternative Device</th>
      </tr>
      <tr>
        <td>&lt; 4 years</td>
        <td>pMDI plus a spacer with face mask</td>
        <td>nebulizer with face mask</td>
      </tr>
      <tr>
        <td>4-6 years</td>
        <td>pMDI plus a spacer with mouthpiece</td>
        <td>
          pMDI plus a spacer with a face mask or, a nebulizer with mouthpiece
          or face mask
        </td>
      </tr>
      <tr>
        <td>Older than 6 years</td>
        <td>
          Dry powder inhaler, or breath actuated pMDI, or pMDI with spacer and
          mouth piece
        </td>
        <td>Nebulizer with mouthpiece</td>
      </tr>
    </table>
    <br />
    <div class="border-btm"></div>
    <br />


    <p class="cpg-headers">
      DAILY DOSES IN MICROGRAMS (MG) OF THE ICS
    </p>


 <table class="cpg-table">
    <tr style="background: #acacac; font-weight: bold; text-align: center;">
        <td>Medication</td>
        <td>Low</td>
        <td>Medium</td>
        <td>High</td>
    </tr>
    <tr>
        <th colspan="4" style="background: #c9c9c9">
            0-4 Years of Age
        </th>
    </tr>
    <tr>
        <td>Budesonide (mg/day, OD or BID)</td>
        <td>0.25-0.5</td>
        <td>&gt; 0.5-1.0</td>
        <td>&gt; 1.0</td>
    </tr>
    <tr>
        <td>Fluticasone (mcg/day, BID)</td>
        <td>176</td>
        <td>&gt; 176-352</td>
        <td>&gt; 352</td>
    </tr>
    <tr>
        <th colspan="4" style="background: #c9c9c9">
            5-11 Years of Age
        </th>
    </tr>
    <tr>
        <td>Beclomethasone (mcg/day BID)</td>
        <td>80-160</td>
        <td>&gt; 160-320</td>
        <td>&gt; 320</td>
    </tr>
    <tr>
        <td>Budesonide (Flexhaler,mcg/day,BID)</td>
        <td>180-360</td>
        <td>&gt; 360-720</td>
        <td>&gt; 720</td>
    </tr>
    <tr>
        <td> Budesonide (Respules,mg/day,BID)</td>
        <td>0.5</td>
        <td>1.0</td>
        <td>2.0</td>
    </tr>
    <tr>
        <td>Ciclesonide (mcg/day,BID)</td>
        <td>80-160</td>
        <td>&gt; 160-320</td>
        <td>&gt; 320</td>
    </tr>
    <tr>
        <td>Flunisolide (mcg/day,BID)</td>
        <td>160</td>
        <td>320-480</td>
        <td>&ge; 480</td>
    </tr>
    <tr>
        <td>Fluticasone (Inhalor) mcg/day, BID
        </td>
        <td>88-176</td>
        <td>&gt; 176-352</td>
        <td>&ge; 352</td>
    </tr>
    <tr>
        <td> Fluticasone (Diskus, mcg/day, BID)</td>
        <td>100-200</td>
        <td>&gt; 200-400</td>
        <td>&gt; 400</td>
    </tr>
    <tr>
        <td>Mometasone (mcg/day, OD or BID)</td>
        <td>110</td>
        <td>220-440</td>
        <td>&gt; 440</td>
    </tr>
    <tr>
        <th colspan="4" style="background: #c9c9c9">
            &ge; 12 Years of Age
        </th>
    </tr>
    <tr>
        <td>Beclomethasone (mcg/day, BID)</td>
        <td>80-240</td>
        <td>&gt; 240-480</td>
        <td>&gt; 480</td>
    </tr>
    <tr>
        <td>Budesonide (Flexhaler,mmcg/day, BID)</td>
        <td>180-540</td>
        <td>&gt; 540-1080</td>
        <td>&gt; 1080</td>
    </tr>
    <tr>
        <td>Budesonide (Respules)</td>
        <td colspan="3">N/A</td>        
    </tr>
    <tr>
        <td>Ciclesonide (mcg/day, BID)</td>
        <td>160-320</td>
        <td>&gt; 320-640</td>
        <td>&gt; 640</td>
    </tr>
    <tr>
        <td>Flunisolide (mcg/day, BID)</td>
        <td>320</td>
        <td>&gt; 320-640</td>
        <td>&gt; 640</td>
    </tr>
    <tr>
        <td>Fluticasone (Inhalor mcg/day, BID)</td>
        <td>88-264</td>
        <td>&gt; 264-440</td>
        <td>&gt; 440</td>
    </tr>
    <tr>
        <td>Fluticasone (Diskus mcg/day, BID)</td>
        <td>100-300</td>
        <td>&gt; 300-500</td>
        <td>&gt; 500</td>
    </tr>
    <tr>
        <td>Mometasone (mcg/day, OD or BID)</td>
        <td>110-220</td>
        <td>&gt; 220-440</td>
        <td>&gt; 440</td>
    </tr>
</table>
    <br /> 
  </div>

  <script src="/js/header.js"></script>
</body>

</html>